Cargando…
Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD
The oral multi-target kinase inhibitor regorafenib, which targets the oncogenic receptor tyrosine kinase (RTK), is an effective therapeutic for patients with advanced gastrointestinal stromal tumors or metastatic colorectal cancer. However, whether regorafenib treatment has beneficial effects on neu...
Autores principales: | Han, Kyung-Min, Kang, Ri Jin, Jeon, Hyongjun, Lee, Hyun-ju, Lee, Ji-Soo, Park, HyunHee, Gak Jeon, Seong, Suk, Kyoungho, Seo, Jinsoo, Hoe, Hyang-Sook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408082/ https://www.ncbi.nlm.nih.gov/pubmed/32660121 http://dx.doi.org/10.3390/cells9071655 |
Ejemplares similares
-
The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice
por: Jeon, Seong Gak, et al.
Publicado: (2020) -
The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD
por: Park, HyunHee, et al.
Publicado: (2020) -
Ibrutinib modulates Aβ/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease
por: Lee, Hyun‐ju, et al.
Publicado: (2021) -
L-Type Ca(2+) Channel Inhibition Rescues the LPS-Induced Neuroinflammatory Response and Impairments in Spatial Memory and Dendritic Spine Formation
por: Kim, Jieun, et al.
Publicado: (2022) -
Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD
por: Lee, Hyun-ju, et al.
Publicado: (2023)